0 261

Cited 16 times in

Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor

DC Field Value Language
dc.contributor.author신정우-
dc.contributor.author이주희-
dc.contributor.author조병철-
dc.date.accessioned2018-05-10T06:35:43Z-
dc.date.available2018-05-10T06:35:43Z-
dc.date.issued2012-
dc.identifier.issn1018-8665-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/158264-
dc.description.abstractBackground : Epidermal growth factor receptor (EGFR) inhibitors have been used as anticancer agents for the treatment of a variety of solid tumors. Related skin toxicities are the most common adverse effects and occur with all EGFR inhibitors. Several treatment approaches, such as antiseptic soaps, topical and oral antibiotics, and topical and oral corticosteroids, have been reported; however, the responses have been varied. Acneiform eruption induced by EGFR inhibitor treatment results from disturbed normal keratinocyte and hair follicle biology and may therefore benefit from local restoration of EGF pathway. Observations : We treated HaCaT cells with EGFR inhibitor and evaluated the expression of EGFR. After treatment of cells with EGFR inhibitor, EGFR expression was increased in a dose-dependent manner. We hypothesized that newly synthesized EGFR, not inhibited by EGFR inhibitors, may perform their biological action in keratinocytes in the presence of additional EGF. In this study, we therefore treated acneiform eruption patients with topical recombinant human EGF (rhEGF) with institutional review board approval. Here, we report three cases of such eruptions who responded to topical rhEGF. Conclusion : Topical rhEGF may be an effective treatment option for EGFR inhibitor-induced acneiform eruption.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherKarger-
dc.relation.isPartOfDERMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAcneiform Eruptions/chemically induced-
dc.subject.MESHAcneiform Eruptions/drug therapy*-
dc.subject.MESHAntineoplastic Agents/adverse effects*-
dc.subject.MESHBlotting, Western-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy-
dc.subject.MESHDrug Eruptions/drug therapy-
dc.subject.MESHEpidermal Growth Factor/therapeutic use*-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHQuinazolines/adverse effects*-
dc.subject.MESHReceptor, Epidermal Growth Factor/antagonists & inhibitors*-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTumor Cells, Cultured-
dc.titleTreatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Dermatology-
dc.contributor.googleauthorJ.U. Shin-
dc.contributor.googleauthorJ.H. Park-
dc.contributor.googleauthorB.-C. Cho-
dc.contributor.googleauthorJ.H. Lee-
dc.identifier.doi10.1159/000342203-
dc.contributor.localIdA02149-
dc.contributor.localIdA03171-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ00708-
dc.identifier.eissn1421-9832-
dc.identifier.pmid23006507-
dc.identifier.urlhttps://www.karger.com/Article/abstract/342203-
dc.contributor.alternativeNameShin, Jung U-
dc.contributor.alternativeNameLee, Ju Hee-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthorShin, Jung U-
dc.contributor.affiliatedAuthorLee, Ju Hee-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.citation.volume225-
dc.citation.number2-
dc.citation.startPage135-
dc.citation.endPage140-
dc.identifier.bibliographicCitationDERMATOLOGY, Vol.225(2) : 135-140, 2012-
dc.identifier.rimsid40646-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.